These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33461829)

  • 41. Linkage facilitation for opioid use disorder in criminal legal system contexts: a primer for researchers, clinicians, and legal practitioners.
    Satcher MF; Belenko S; Coetzer-Liversage A; Wilson KJ; McCart MR; Drazdowski TK; Fallin-Bennett A; Zaller N; Schultheis AM; Hogue A; Vest N; Sheidow AJ; Del Pozo B; Watson DP; Hibbard PF; Stevens R; Stein LAR
    Health Justice; 2024 Aug; 12(1):36. PubMed ID: 39207608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The cascade of care for opioid use disorder among youth in British Columbia, 2018.
    Krebs E; Min JE; Zhou H; Davison C; McGowan G; Nosyk B
    J Subst Abuse Treat; 2021 Nov; 130():108404. PubMed ID: 34118696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.
    Lee JD; Malone M; McDonald R; Cheng A; Vasudevan K; Tofighi B; Garment A; Porter B; Goldfeld KS; Matteo M; Mangat J; Katyal M; Giftos J; MacDonald R
    JAMA Netw Open; 2021 Sep; 4(9):e2123032. PubMed ID: 34495340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Providing peer navigation services to women with a history of opioid misuse pre- and post-release from jail: A program description.
    Tillson M; Fallin-Bennett A; Staton M
    J Clin Transl Sci; 2022; 6(1):e106. PubMed ID: 36128341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
    Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
    Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utilizing Recovery Management Checkups to shorten the cycle of relapse, treatment reentry, and recovery.
    Scott CK; Dennis ML; Foss MA
    Drug Alcohol Depend; 2005 Jun; 78(3):325-38. PubMed ID: 15893164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and use of a checklist for the implementation of medication for opioid use disorder in jails.
    Ludwig A; Monico LB; Blue T; Gordon MS; Schwartz RP; Mitchell SG
    Implement Res Pract; 2022; 3():26334895221101214. PubMed ID: 37091098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fostering MOUD use in justice populations: Assessing the comparative effectiveness of two favored implementation strategies to increase MOUD use.
    Molfenter T; Vechinski J; Taxman FS; Breno AJ; Shaw CC; Perez HA
    J Subst Abuse Treat; 2021 Sep; 128():108370. PubMed ID: 33762145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Feasibility and Acceptability of a Digital Health Intervention to Promote Continued Engagement in Medication for Opioid Use Disorder Following Release From Jail/Prison.
    Langdon KJ; Jiménez Muñoz P; Block A; Scherzer C; Ramsey S
    Subst Abuse; 2022; 16():11782218221127111. PubMed ID: 36188441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The economic costs of jail-based methadone maintenance treatment.
    Horn BP; Li X; Mamun S; McCrady B; French MT
    Am J Drug Alcohol Abuse; 2018; 44(6):611-618. PubMed ID: 30024783
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The interaction of co-occurring mental disorders and recovery management checkups on substance abuse treatment participation and recovery.
    Rush BR; Dennis ML; Scott CK; Castel S; Funk RR
    Eval Rev; 2008 Feb; 32(1):7-38. PubMed ID: 18198169
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults.
    Elkington KS; Nunes E; Schachar A; Ryan ME; Garcia A; Van DeVelde K; Reilly D; O'Grady M; Williams AR; Tross S; Wilson P; Cohall R; Cohall A; Wainberg M
    J Subst Abuse Treat; 2021 Sep; 128():108277. PubMed ID: 33487516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.
    Cheng A; Badolato R; Segoshi A; McDonald R; Malone M; Vasudevan K; Badiei B; Sugarman A; Macdonald R; Mangat J; Giftos J; Lee JD; Tofighi B
    Addict Sci Clin Pract; 2022 Jan; 17(1):4. PubMed ID: 35093164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Addressing opioid use disorder among rural pregnant and postpartum women: a study protocol.
    Bryan MA; Smid MC; Cheng M; Fortenberry KT; Kenney A; Muniyappa B; Pendergrass D; Gordon AJ; Cochran G
    Addict Sci Clin Pract; 2020 Oct; 15(1):33. PubMed ID: 33129355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Screening for Opioid Use Disorder in the Largest Jail in Arkansas: A Brief Report.
    Zaller N; Donadeo K; Coffey J; Zielinski M; Brinkley-Rubinstein L
    J Correct Health Care; 2019 Jul; 25(3):214-218. PubMed ID: 31195879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
    Smith A; Hansen J; Colvard M
    J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder.
    Friesen EL; Kurdyak P
    Drug Alcohol Depend; 2020 Nov; 216():108244. PubMed ID: 32861134
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes In Health Services Use After Receipt Of Medications For Opioid Use Disorder In A Statewide Correctional System.
    Howell BA; Martin RA; Lebeau R; Truong AQ; Wang EA; Rich JD; Clarke JG
    Health Aff (Millwood); 2021 Aug; 40(8):1304-1311. PubMed ID: 34339247
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US.
    Stahler GJ; Mennis J
    Drug Alcohol Depend; 2020 Jul; 212():108067. PubMed ID: 32445926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.